BONE MINERAL DENSITY IN CHILDREN AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
造血干细胞移植后儿童的骨矿物质密度
基本信息
- 批准号:7375877
- 负责人:
- 金额:$ 0.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-12-01 至 2006-11-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. With the use of more effective anti-cancer therapy and hematopoietic stem cell transplantation (HSCT), more children survive their primary malignancies or are cured of the primary heatologic or metabolic disorders. As a consequence of improved survival, the population of post-HCST patients is increasing and secondary effects of treatment become an important issue. One of the metabolic complications of HSCT is osteoporosis. Adequate bome mineralization is of particular importance in the pediatric population because 45% of peak bone mineral accretion occurs during the most active growth during puberty. Patients who do not reach the optimal bone mineral density (BMD) during this period may suffer from a lifelong debilitating condition. The knowledge of risk factors, incidence, timing, the mechanisms and the magnitude of bone loss following HSCT in children is very limited. At present, no prospective studies have been reported on BMD in children after HSCT. The goal of this pilot study is to collect preliminary prospective data on BMD in children after HSCT. The goal of this pilot study is to collect preliminary prospective data on BMD and markers of bone turnover that would constitute the basis for an application for the external grant support. Each patient will have 4 appointments which will be part of a routine care before and after stem cell transplant, that is 100 days, 6 months, and 12 months after transplant. Each visit will involve a physical examination, blood and urine tests to assess the condition of the bones and various endocrine glands related to the bone growth. In addition, during 3 out of 4 visits, the patients will have a DEXA scan of the bones, which is a non-invasive, painless, safe, and quick method to determine the mineral content of the bones and the risk of osteoporosis. During the initial visit, and at a 1-year follow up visit, the x-ray of the left wrist will be taken to determine the age of the bones, which will be important to interpret the results of the DEXA scan.
本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者(PI)可能已经从另一个NIH来源获得了主要资金,因此可以在其他CRISP条目中表示。列出的机构是中心的,不一定是研究者的机构。随着更有效的抗癌治疗和造血干细胞移植(HSCT)的使用,更多的儿童在原发恶性肿瘤中存活下来或治愈了原发热学或代谢紊乱。由于生存率的提高,hcst后患者的数量正在增加,治疗的继发效应成为一个重要问题。骨质疏松是造血干细胞移植的代谢并发症之一。充足的家庭矿化对儿科人群尤其重要,因为45%的骨矿物质峰值增加发生在青春期生长最活跃的时期。在此期间没有达到最佳骨密度(BMD)的患者可能会遭受终身衰弱的折磨。对儿童造血干细胞移植后骨质流失的危险因素、发生率、时间、机制和程度的了解非常有限。目前,尚未有关于HSCT后儿童骨密度的前瞻性研究报道。本初步研究的目的是收集HSCT后儿童骨密度的初步前瞻性数据。本试点研究的目的是收集骨密度和骨转换标志物的初步前瞻性数据,为申请外部资助支持奠定基础。每个患者将有4次预约,这将是干细胞移植前后的常规护理的一部分,即移植后100天,6个月和12个月。每次访问将包括身体检查,血液和尿液测试,以评估骨骼和与骨骼生长有关的各种内分泌腺体的状况。此外,在4次就诊中有3次,患者将进行DEXA骨骼扫描,这是一种无创、无痛、安全、快速的方法,可以确定骨骼的矿物质含量和骨质疏松症的风险。在初次就诊和1年随访期间,将拍摄左手腕x光片以确定骨骼的年龄,这对解释DEXA扫描结果很重要。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Anna Petryk其他文献
Anna Petryk的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Anna Petryk', 18)}}的其他基金
Prevention of HPE in a mouse model susceptible to retinoic acid teratogenicity
在易受视黄酸致畸影响的小鼠模型中预防 HPE
- 批准号:
8729720 - 财政年份:2013
- 资助金额:
$ 0.23万 - 项目类别:
TWISTED GASTRULATION AND MANDIBULAR ARCH MORPHOGENESIS
扭曲的原肠胚形成和下颌骨形态发生
- 批准号:
7409704 - 财政年份:2007
- 资助金额:
$ 0.23万 - 项目类别:
TWISTED GASTRULATION AND MANDIBULAR ARCH MORPHOGENESIS
扭曲的原肠胚形成和下颌骨形态发生
- 批准号:
7619290 - 财政年份:2007
- 资助金额:
$ 0.23万 - 项目类别:
TWISTED GASTRULATION AND MANDIBULAR ARCH MORPHOGENESIS
扭曲的原肠胚形成和下颌骨形态发生
- 批准号:
7845479 - 财政年份:2007
- 资助金额:
$ 0.23万 - 项目类别:
TWISTED GASTRULATION AND MANDIBULAR ARCH MORPHOGENESIS
扭曲的原肠胚形成和下颌骨形态发生
- 批准号:
7194587 - 财政年份:2007
- 资助金额:
$ 0.23万 - 项目类别:
TWISTED GASTRULATION AND MANDIBULAR ARCH MORPHOGENESIS
扭曲的原肠胚形成和下颌骨形态发生
- 批准号:
8080801 - 财政年份:2007
- 资助金额:
$ 0.23万 - 项目类别:
GLUCOSE AND INSULIN ABNORMALITIES IN FANCONI ANEMIA
范可尼贫血的血糖和胰岛素异常
- 批准号:
7606005 - 财政年份:2006
- 资助金额:
$ 0.23万 - 项目类别:
GLUCOSE AND INSULIN ABNORMALITIES IN FANCONI ANEMIA
范可尼贫血的血糖和胰岛素异常
- 批准号:
7375937 - 财政年份:2005
- 资助金额:
$ 0.23万 - 项目类别:
BONE MINERAL DENSITY IN CHILDREN AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
造血干细胞移植后儿童的骨矿物质密度
- 批准号:
7206453 - 财政年份:2005
- 资助金额:
$ 0.23万 - 项目类别:
The role of Twisted Gastrulation in Mouse Development
扭曲原肠胚形成在小鼠发育中的作用
- 批准号:
6696589 - 财政年份:2003
- 资助金额:
$ 0.23万 - 项目类别:
相似海外基金
The diagnosis and treatment of postoperative bone mineral density decrease after spine surgery
脊柱术后骨密度下降的诊治
- 批准号:
23K15697 - 财政年份:2023
- 资助金额:
$ 0.23万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Determining Bone Loss and Bone Mineral Density Recovery Following Repeat Pregnancy/Lactation Among HIV Women on ART
确定接受 ART 治疗的 HIV 妇女重复怀孕/哺乳后的骨质流失和骨矿物质密度恢复情况
- 批准号:
10805834 - 财政年份:2023
- 资助金额:
$ 0.23万 - 项目类别:
Study of the relationship between resistance training and bone mineral density and bone quality using an ultrasonic bone measurement system
使用超声波骨测量系统研究阻力训练与骨矿物质密度和骨质量之间的关系
- 批准号:
23K10699 - 财政年份:2023
- 资助金额:
$ 0.23万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
DDTBMQ000054: Regulatory qualification for DXA bone mineral density as a surrogate endpoint for fracture risk in osteoporosis trials
DDTBMQ000054:DXA 骨矿物质密度作为骨质疏松症试验中骨折风险替代终点的监管资格
- 批准号:
10623740 - 财政年份:2022
- 资助金额:
$ 0.23万 - 项目类别:
The influence of irisin/FNDC5 on bone mineral density and fracture risk in individuals with spinal cord injury
鸢尾素/FNDC5对脊髓损伤个体骨矿物质密度和骨折风险的影响
- 批准号:
10609491 - 财政年份:2022
- 资助金额:
$ 0.23万 - 项目类别:
Minimising bone mineral density loss in traumatic amputees: a randomised controlled feasibility trial
最大限度地减少创伤性截肢者的骨矿物质密度损失:一项随机对照可行性试验
- 批准号:
EP/X027155/1 - 财政年份:2022
- 资助金额:
$ 0.23万 - 项目类别:
Fellowship
Functional Dissection of the MARK3 GWAS Locus for Bone Mineral Density
MARK3 GWAS 基因座骨矿物质密度的功能剖析
- 批准号:
10260104 - 财政年份:2021
- 资助金额:
$ 0.23万 - 项目类别:
Functional Dissection of the MARK3 GWAS Locus for Bone Mineral Density
MARK3 GWAS 基因座骨矿物质密度的功能剖析
- 批准号:
10512047 - 财政年份:2021
- 资助金额:
$ 0.23万 - 项目类别:
Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI
Romosozumab 可改善慢性 SCI 患者的骨矿物质密度和结构
- 批准号:
10418624 - 财政年份:2020
- 资助金额:
$ 0.23万 - 项目类别:
Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI
Romosozumab 可改善慢性 SCI 患者的骨矿物质密度和结构
- 批准号:
10664874 - 财政年份:2020
- 资助金额:
$ 0.23万 - 项目类别: